循環器治療薬の最前線SPRINT試験とミトコンドリア病治療薬MA-5 by 柳澤  輝行
循環器治療薬の最前線SPRINT試験とミトコンドリア
病治療薬MA-5
著者 柳澤  輝行
URL http://hdl.handle.net/10097/62593
臨床実習前特別講義:4年生最終講義 
循環器治療薬の最前線 
• SPRINT: Systolic Blood Pressure Intervention Trialについて  
– N Engl J Med 2015;373:2103-16 
• オーキシン（植物ホルモン）から誘導した合成化合物
のミトコンドリア病治療薬MA-5について 
– Tohoku J Exp Med. 2015 July;236(3):225-32. 
– J Am Soc Nephrol. Published online 2015 Nov 25. 
– tohokuuniv-press20151126_01web 
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SPRINT: Systolic Blood Pressure 
Intervention Trialについて 
• SPRINT: Systolic Blood Pressure Intervention Trial  
–フラミンガム研究、framinghamheartstudy 
–高血圧患者、120mmHg未満か140mmHgか？ 
– SPRINT試験対象者 
–Medications（1.8剤から3剤へ） 
–一次評価項目も全死亡率も3/4に 
–治療に伴う有害事象は約2倍 
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artstudy.org/risk-
functions/cardiovascular-
disease/10-year-risk.php 
心血管合併症に対する危険因子の影響  
（40歳男性千人､18年間）フラミンガム研究 
脳 
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http://cvdrisk.nhlbi.nih.gov/ 
http://cvdrisk.nhlbi.nih.gov/ 
Background: The most appropriate targets for systolic blood pressure to reduce 
cardiovascular morbidity and mortality among persons without diabetes remain 
uncertain. 
Methods : We randomly assigned 9361 persons with a systolic blood pressure of 130 
mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a 
systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a 
target of less than 140 mm Hg (standard treatment). The primary composite 
outcome was myocardial infarction, other acute coronary syndromes, 
stroke, heart failure, or death from cardiovascular causes. 
SPRINT試験対象者 
日経メディカル（20151203）より改変 
SBP in the Two Treatment Groups over the Course of the Trial. 
Framingham 10-yr CV disease risk score: 20.1±10.9% vs. 20.1±10.8% 
Medications（1.8剤から3剤へ） 
• Chlorthalidone 
– loop diuretics (for participants with advanced 
chronic kidney disease) 
– β-adrenergic blockers (for those with coronary 
artery disease) 
• Amlodipine 
• ACE-I  
• Azilsartan or Azilsartan + chlorthalidone 
Utilization of Antihypertensive Medication Classes at 
Most Recent Visit 
Utilization of Antihypertensive Medication Classes at Most Recent Visit 
Primary Outcome and Death from Any Cause. 
At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the 
intensive-treatment group (ITG) and 136.2 mm Hg in the standard-
treatment group (STG).  
The intervention was stopped early after a median follow-up of 3.26 
years owing to a significantly lower rate of the primary composite 
outcome in the ITG than in the STG (1.65% per year vs. 2.19% per year; 
P<0.001). All-cause mortality was also significantly lower in the ITG 
(1.04% per year vs. 1.40% per year; P=0.003).  
 
一次評価項目も全死亡率も3/4 
日経メディカル（20151203）より改変 
ITG STG 
Forest Plot of Primary Outcome According to Subgroups. 
after a median follow-up of 3.26 years 
Causes of Death 
coronary heart disease  
治療に伴う有害事象は約2倍 
Rates of serious adverse events of 
hypotension, syncope, electrolyte 
abnormalities, and acute kidney injury or 
failure, but not of injurious falls, were 
higher in the ITG than in the STG (1072 
(22.9%) vs. 554 (11.8%); hazard ratio, 1.94 
(<0.001) from Table S5). 
Table S5. Serious Adverse Events and Conditions of Interest 
Classified as Possibly or Definitely Related to the Intervention 
Outcomes Data from SPRINT and the ACCORD Trial and 
Combined Data from Both Trials 
Systolic Blood Pressure Intervention Trial (SPRINT)  
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial; T2DM 
NEJM. 2015;373:2175-8. 
Conclusions: Among patients at high risk for cardiovascular events 
but without diabetes, targeting a systolic blood pressure of less than 
120 mm Hg, as compared with less than 140 mm Hg, resulted in 
lower rates of fatal and nonfatal major cardiovascular events and 
death from any cause, although significantly higher rates of some 
adverse events were observed in the intensive-treatment group. 
臨床実習前特別講義:4年生最終講義 
• オーキシン（植物ホルモン）から誘導した合成化合
物のミトコンドリア病治療薬MA-5について 
–河北新報の紙面 
– Tohoku J Exp Med. 2015 July;236(3):225-32. 
– J Am Soc Nephrol. Published online 2015 Nov 25. 
– tohokuuniv-press20151126_01web 
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Mitochondria are key organelles implicated in a variety of processes related to 
energy and free radical generation, the regulation of apoptosis, and various 
signaling pathways.  
Mitochondrial dysfunction increases cellular oxidative stress and depletes ATP in a 
variety of inherited mitochondrial diseases and also in many other metabolic and 
neurodegenerative diseases. Mitochondrial diseases are characterized by the 
dysfunction of the mitochondrial respiratory chain, caused by mutations in the 
genes encoded by either nuclear DNA or mitochondrial DNA.  
We have hypothesized that chemicals that increase the cellular ATP 
levels may ameliorate the mitochondrial dysfunction seen in 
mitochondrial diseases.  
To search for the potential drugs for mitochondrial diseases, we 
screened an in-house chemical library of indole-3-acetic-acid 
analogs by measuring the cellular ATP levels in Hep3B human 
hepatocellular carcinoma cells.  
We have thus identified mitochonic acid 5 (MA-5), 4-(2,4-
difluorophenyl)-2-(1H-indol-3-yl)-4-oxobutanoic acid, as a potential 
drug for enhancing ATP production. MA-5 is a newly synthesized 
derivative of the plant hormone, indole-3-acetic acid.  
Importantly, MA-5 improved the survival of fibroblasts established 
from patients with mitochondrial diseases under the stress-induced 
condition, including Leigh syndrome, MELAS (myopathy 
encephalopathy lactic acidosis and stroke-like episodes), Leber’s 
hereditary optic neuropathy, and Kearns-Sayre syndrome.  
Auxin (indol-3-acetic acid) 
細胞内タンパク質のSH基を適当な酸化状態に保つ 
グルタチオン 
Glutathione (GSH) 
2GSH ⇔ GSSG＋2H 
H2N 
トリプトファン 
Mitochonic acid (MA-5) 
細胞障害試薬、L-buthionine-(S,R)-sulfoximine  
(BSO, glutathione synthesis inhibitor, 100 μM)  
MA-5 increases ATP and 
the survival of fibroblasts 
from mitochondrial 
diseases. EC50 = 2.3 μM 
The improved survival was associated with the increased 
cellular ATP levels.  
Moreover, MA-5 increased the survival of mitochondrial 
disease fibroblasts even under the inhibition of the 
oxidative phosphorylation or the electron transport 
chain.  
These data suggest that MA-5 could be a therapeutic 
drug for mitochondrial diseases that exerts its effect in a 
manner different from anti-oxidant therapy. 
J Am Soc Nephrol 27: ccc–ccc, 2015. doi: 10.1681/ASN.2015060623 
Mitochondrial dysfunction causes increased oxidative stress and 
depletion of ATP, which are involved in the etiology of a variety of 
renal diseases, such as CKD, AKI, and steroid-resistant nephrotic 
syndrome. Antioxidant therapies are being investigated, but clinical 
outcomes have yet to be determined.  
Recently, we reported that a newly synthesized indole 
derivative, mitochonic acid 5 (MA-5), increases cellular ATP 
level and survival of fibroblasts from patients with 
mitochondrial disease. MA-5 modulates mitochondrial ATP 
synthesis independently of oxidative phosphorylation and 
the electron transport chain.  
Here, we further investigated the mechanism of action for 
MA-5. Administration of MA-5 to an ischemia-reperfusion 
injury model and a cisplatin-induced nephropathy model 
improved renal function.  
In in vitro bioenergetic studies, MA-5 facilitated ATP 
production and reduced the level of mitochondrial reactive 
oxygen species (ROS) without affecting activity of 
mitochondrial complexes I-IV.  
MA-5 binds with mitofilin 
Mitofilin forms a core complex in the mitochondrial inner membrane 
organizing system (MINOS) 
蛍光基 
MA-5 improved respiration of cardiac and renal 
cell in Mitomice 
A mitochondrial 
disease model 
(Mitomice with 
mitochondrial DNA 
deletion that mimics 
typical human 
mitochondrial 
disease phenotype) 
MA-5 improve respiration in Heart & Kidney 
Succinate dehydrogenase 
(SDH) and COX activity were 
assessed by immunostaining 
of the heart tissues (Left) 
and SDH (right) of the kidny 
tissues from Mitomice 
Schematic model of the action of MA-5. MA-5 interacts with mitofilin 
and modifies the MINOS complex. 
Additional assays revealed that MA-5 targets the 
mitochondrial protein mitofilin at the crista junction of the 
inner membrane. In Hep3B cells, overexpression of mitofilin 
increased the basal ATP level, and treatment with MA-5 
amplified this effect.  
In a unique mitochondrial disease model mouse, MA-5 
improved the reduced cardiac and renal mitochondrial 
respiration and seemed to prolong survival.  
These results suggest that MA-5 functions in a manner 
differing from that of antioxidant therapy and could be a 
novel therapeutic drug for the treatment of cardiac and 
renal diseases associated with mitochondrial dysfunction. 
J Am Soc Nephrol 27: ccc–ccc, 2015. doi: 10.1681/ASN.2015060623 
MegaBuster from an orphan drug 
極めて少数の難病治療から多数の一般病治療薬へ 
 
サプライズがありました。花の色は黄、紫、赤オレンジ
色で、それぞれ窒素（硝酸薬）、カリウム、カルシウム
だそうで、NKハイブリッド、細胞内Ca濃度の象徴として
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